The Pathogenetic Role of Apelin in the Development of Hypertension

S.M. Koval, K.O. Yushko, T.H. Starchenko, I.A. Korniichuk, O.V. Lytvynova


The article presents the analysis of the results of international, national and own studies on the pathogenetic role of peptide apelin in the development of hypertension and its complications. Apelin interactions with the blood pressure regulation mechanisms, the renin-angiotensin system components, the target organ damage processes were shown. The possibility of applying the apelin and its synthetic analogues as a potentially new class of drugs for the treatment of hypertension and its complications has been discussed.


apelin; hypertension; renin-angiotensin system; cardiac remodeling; therapeutic options


Koval' SM, Yushko KO, Starchenko TH, Shut' IV. [Blood apelin levels in hypertensive patients with and without type 2 diabetes mellitus]. Ukrainian therapeutical journal. 2015;1(44):49-54. Ukrainian.

Koval' SM, Yushko KO, Starchenko TH. [Endogenous peptide apelin and pathological cardiac remodeling in hypertensive patients with diabetes mellitus type 2]. International journal of endocrinology. 2015;5(69):37-40. Ukrainian.

Lakomkin VL, Abramov AA, Lukoshkova EV, Lakomkin SV, Gramovich VV, Vyborov ON, Undrovinas NA, Ermishkin VV, Tsyplenkova VG, Shirinsky VP, Kapelko VI. [The Action of Apelin-12 and Its Analog on Hemodynamics and Cardiac Contractile Function of Rats With Isoproterenol-Induced Myocardial Lesion]. Kardiologiia. 2015;55(6):54-62. Russian.

Koval' SM, Yushko KO, Starchenko TH, Shut' IV, Vysots'ka OV, Strashnyenko HM, inventors; Government Institution "L.T.Malaya Therapy National Institute of the NAMS of Ukraine" assignee. The method for predicting the risk of left ventricular hypertrophy in the hypertensive patients with type 2 diabetes mellitus. Ukraine patent UA102009.2015 Oct 12. A61B 5/02, G01N 33/48. Ukrainian.

Sidorova MV, Az'muko AA, Pal'keeva ME, Molokoedov AS, Bushuev VN, Dvoriantsev SN, Shul'zhenko VS, Pelogeĭkina VS, Pisarenko OI, Bespalova ZhD. [Synthesis and cardioprotective properties of apelin-12 and its structural analogs]. Russian Journal of Bioorganic Chemistry. 2012;38(1):40-51. Russian.

Tereschenko SN, Masenko VP, Cherkavskaya OV, Shashkova NV. [Apelin is a novel protein regulating cardiovascular system]. Therapeutic Archiv. 2009;81(9):68—72. Russian.

Fadieienko G, Gridniev O. [Features manifestations comorbid currents of gastroesophageal reflux disease and arterial hypertension depending on the degree of arterial hypertension]. Georgian Med News. 2015;(248):21-29. Russian.

Akcilar R, Turgut S, Caner V, Akcilar A, Ayada C, Elmas L, Ozcan TO. Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clin Exp Hypertens. 2013;35(7):550–557.

Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, Greve J, Robbins R, Patterson AJ, Bernstein D, Quertermous T. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res. 2005;65(1):73-82.

Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, Vaudry H, Corvol P, Llorens-Cortes C. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol (JASN). 2008;19(5):1015–1024.

Barnes G, Japp AG, Newby DE. Translational promise of the apelin/APJ system. Heart. 2010;96(13):1011-6.

Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, Singer M, Glen RC, Wilkinson IB, Davenport AP. Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. Hypertension. 2015;65(4):834-40.

Burrell LM, Risvanis J, Dean RG, Patel SK, Velkoska E, Johnston CI. Age-dependent regulation of renal vasopressin V(1A) and V(2) receptors in rats with genetic hypertension: implications for the treatment of hypertension. J Am Soc Hypertens (JASH). 2013;7(1):3–13.

Cao J, Li H, Chen L. Targeting drugs to APJ receptor: the prospect of treatment of hypertension and other cardiovascular diseases. Curr Drug Targets. 2015;16(2):148-55.

Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Investig. 2008;118(10):3343–3354.

Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P, Parini A, Kunduzova O. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett. 2010;584(11):2363-70.

Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T. Effects of olmesartan on apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with endstage heart failure. J Cardiovasc Pharmacol. 2010;55(1):83–88.

Gomolka RS, Cudnoch-Jedrzejewska A, Czarzasta K, Szczepanska-Sadowska E. Reduction of pressor response to stress by centrally acting apelin in spontaneously hypertensive rats. J Basic Clin Physiol Pharmacol. 2015;26(3):233-6.

Han X, Zhang DL, Yin DX, Zhang QD, Liu WH. Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA. Can J Physiol Pharmacol. 2013;91(9):708–714.

Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T. Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens. 2011;2011:391762. doi: 10.4061/2011/391762.

Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, Llorens-Cortes C. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int. 2008;74(4):486-94.

Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K, Kasuya Y, Mochizuki N, Fukamizu A. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279(25):26274–26279.

Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol. 2006;41(5):798-806.

Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;121(16):1818-27.

Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, Yu F, Duan XH, Tang CS, Qi YF Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007;28(10):2023–2029.

Jia J, Men C, Tang KT, Zhan YY. Apelin polymorphism predicts blood pressure response to losartan in older Chinese women with essential hypertension. Genet Mol Res. 2015;14(2):6561-8.

Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J. 2012;76(1):137-44.

Kosmala W., Kotwica T., Przewlocka-Kosmala M. Usefulness of Apelin measurement in identification of subclinical LV dysfunction in essential hypertension. European Heart Journal. 2009;30(Abstract Supplement): 132-132.

Li L., Zeng H., Chen J.X. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2012; 303(5):605-18.

Li WW, Niu WQ, Zhang Y, Wu S, Gao PJ, Zhu DL. Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens. 2009;27(6):1194–1201.

Liakos CI, Sanidas EA, Perrea DN, Grassos CA, Chantziara V, Viniou NA, Barbetseas JD, Papadopoulos DP. Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure. Am J Hypertens. 2015; pii: hpv136. [Epub ahead of print].

Llorens-Cortes C, Kordon C. Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems. J Neuroendocrinol. 2008;20(3):279-89.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23(1):3-16.

Modgil A, Guo L, O'Rourke ST, Sun C. Apelin-13 inhibits large-conductance Ca2+-activated K+ channels in cerebral artery smooth muscle cells via a PI3-kinase dependent mechanism. PLoS One. 2013;8(12):e83051.

Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5–12.

Nagano K, Ishida J, Unno M, Matsukura T, Fukamizu A. Apelin elevates blood pressure in ICR mice with LNAMEinduced endothelial dysfunction. Mol Med Rep. 2013;7(5):1371–1375.

Papadopoulos DP, Mourouzis I, Faselis C, Perrea D, Makris T, Tsioufis C, Papademetriou V Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich). 2013;15(5):333–336.

Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH, Wanecq E, Valet P, Parini A, Kunduzova O. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J. 2012;33(18):2360-9.

Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62(3):331-42.

Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens. 2011;29(5):971-9.

Sato T, Suzuki T, Watanabe H, Kadowaki A, Fukamizu A, Liu PP, Kimura A, Ito H, Penninger JM, Imai Y, Kuba K. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Investig. 2013;123(12):5203–5211.

Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods CE, Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP, Kaliman P, Bodmer R, Smith LH, Ashley E, Mercola M, Brown JH, Ruiz-Lozano P. APJ acts as a dual receptor in cardiac hypertrophy. Nature. 2012;488(7411):394-8.

Scimia MC, Blass BE, Koch WJ. Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy. Expert Rev Cardiovasc Ther. 2014;12(6):733-41.

Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, Smith LH. Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens. 2011;29(4):724-31.

Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, Ercin CN, Dogru T, Kilic S, Uckaya G, Yilmaz MI, Erbil MK, Kutlu M. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32(3):179-83.

Takatori S, Zamami Y, Hashikawa-Hobara N, Kawasaki H Insulin resistance-induced hypertension and a role of perivascular CGRPergic nerves. Curr Protein Pept Sci. 2013; 14(4):275–281.

Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99(2–3):87–92.

Togashi N, Maeda T, Yoshida H, Koyama M, Tanaka M, Furuhashi M, Shimamoto K, Miura T Angiotensin II receptor activation in youth triggers persistent insulin resistance and hypertension — a legacy effect? Hypertens Res. 2012;35(3):334–340.

Wang L, Hou L, Li H, Chen J, Kelly TN, Jaquish CE, Rao DC, Hixson JE, Hu D, Chen CS, Gu C, Chen S, Lu X, Whelton PK, He J, Lu F, Huang J, Liu DP, Gu D. Genetic variants in the renin–angiotensin system and blood pressure reactions to the cold pressor test. J Hypertens. 2010;28(12):2422–2428.

Wu D, He L, Chen L. Apelin/APJ system: a promising therapy target for hypertension. Mol Biol Rep. 2014;41(10):6691-703.

Xiaoping C, Qing P. Relationship between microalbuminuria and apelin in primary hypertensive patients. International Journal of Cardiology. 2009;137(Suppl. 1):S32-S32.

Xun P, Wu Y, He Q, He K. Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies. Am J Clin Nutr. 2013;98(6):1543–1554.

Yang B, Liu X, Li M, Yang Y, Na X, Wang Y. Genetic association of rs1800780 (A/G) polymorphism of the eNOS gene with susceptibility to essential hypertension in a Chinese Han population. Biochem Genet. 2013;doi:10.1007/s10528-013-9628-3.

Ye L, Ding F, Zhang L, Shen A, Yao H, Deng L, Ding Y. Serum apelin is associated with left ventricular hypertrophy in untreated hypertension patients. J Transl Med. 2015;13:290. doi: 10.1186/s12967-015-0635-5.

Yue P, Jin H, Aillaud M, Deng AC, Azuma J, Asagami T, Kundu RK, Reaven GM, Quertermous T, Tsao PS. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010; 298(1):E59–E67.

Zhang Q, Yao F, Raizada MK, O’Rourke ST, Sun C. Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res. 2009;104(12):1421–1428.

Zhong JC, Huang DY, Liu GF, Jin HY, Yang YM, Li YF, Song XH, Du K. Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc Res. 2005;65(3):743–750.

Zhu P, Huang F, Lin F, Yuan Y, Chen F, Li Q Plasma apelin levels, blood pressure and cardiovascular risk factors in a coastal Chinese population. Ann Med. 2013;45(7):494-498

Zhu P, Lin F, Huang F, Huang Q, Li Q, Gao Z, Chen F. Apelin and APLN single nucleotide polymorphisms and combined hypertension and central retinal artery stenosis in a Chinese population.Clin Exp Hypertens. 2015;37(4):280-7.

Zhu S, Sun F, Li W, Cao Y, Wang C, Wang Y, Liang D, Zhang R, Zhang S, Wang H, Cao F Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol Cell Biochem. 2011;353(1–2):305–313.



  • There are currently no refbacks.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


 Яндекс.МетрикаSeo анализ сайта Рейтинг